Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 7/20 | 0.70 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.69 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.69 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.67 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.65 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.65 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.65 |
| ▸ | LDHA | P00338 | 1/20 | 0.65 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.65 |
| ▸ | FBP1 | P09467 | 1/20 | 0.65 |
| ▸ | SRC | P12931 | 1/20 | 0.65 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.65 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.65 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.65 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.65 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29564165 | 1.00 | DNPH1 (0.70) | DNPH1P2RX3P2RX2TAS1R3TAS1R1 | |
| SCHEMBL25356221 | 0.93 | P2RX3 (0.79) | DNPH1P2RX3P2RX2TAS1R3TAS1R1 | |
| SCHEMBL25358180 | 0.93 | P2RX3 (0.81) | DNPH1P2RX3P2RX2TRPM2SRC | |
| SCHEMBL30150740 | 0.92 | ADORA1 (0.68) | DNPH1P2RX3P2RX2TAS1R3TAS1R1 | |
| SCHEMBL8780682 | 0.89 | DNPH1 (0.77) | DNPH1P2RX3P2RX2TAS1R3TAS1R1 | |
| SCHEMBL8780669 | 0.89 | DNPH1 (0.77) | DNPH1P2RX3P2RX2TAS1R3TAS1R1 | |
| SCHEMBL4820592 | 0.88 | DNPH1 (0.73) | DNPH1P2RX3P2RX2TAS1R3TAS1R1 | |
| SCHEMBL6707282 | 0.88 | DNPH1 (0.73) | DNPH1P2RX3P2RX2TAS1R3TAS1R1 | |
| SCHEMBL25286647 | 0.87 | DNPH1 (0.71) | DNPH1P2RX3P2RX2TAS1R3TAS1R1 | |
| SCHEMBL20705924 | 0.87 | P2RX3 (0.72) | DNPH1P2RX3P2RX2TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203638-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | VDF FUTURECEUTICALS, INC. (US) | 2009-08-13 | — | — | US | claimed |
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | VDF FUTURECEUTICALS | 2007-07-12 | — | — | US | claimed |
| WO-2005020892-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| US-12201075-B2 | Methods and compositions for axillary shoot micropropagation of Cannabis and related plants | JUSHI IP, LLC (US) | 2025-01-21 | — | — | US | disclosed |
| US-20230265444-A1 | GENE-EDITING IN CANNABIS PLANT | CANOPY GROWTH CORPORATION (CA) | 2023-08-24 | — | — | US | disclosed |
| US-20220110278-A1 | METHODS AND COMPOSITIONS FOR AXILLARY SHOOT MICROPROPAGATION OF CANNABIS AND RELATED PLANTS | JUSHI IP, LLC | 2022-04-14 | — | — | US | disclosed |
| US-20210277351-A1 | METHODS FOR HETEROTROPHICALLY CULTURING EUGLENA IN HYBRID MEDIA | NOBLEGEN INC (CA) | 2021-09-09 | — | — | US | disclosed |
| US-8088752-B2 | Methods for metabolic modulation | VDF FUTURECEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090208620-A1 | Alimentary Compositions and Methods For Metabolic Modulation | VDF FUTURECEUTICALS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090203638-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | VDF FUTURECEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20070184067-A1 | Alimentary compositions and methods for metabolic modulation | VDF FUTURECEUTICALS | 2007-08-09 | — | — | US | disclosed |
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | VDF FUTURECEUTICALS | 2007-07-12 | — | — | US | disclosed |
| WO-2005020892-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005016268-A2 | ALIMENTARY COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | GPR119, PRKAG2, PRKAG1 | DNPH1 3996/4885P2RX3 287/4885P2RX2 193/4885 |
| US-20090203638-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | GPR119, PRKAG2, GCKR | DNPH1 3917/4885P2RX3 247/4885P2RX2 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.